Soto Esteban, Halliday-Simmonds Iona, Francis Stewart, Fraites Trellor, Martínez-López Beatriz, Wiles Judy, Hawke John P, Endris Richard D
a Department of Medicine and Epidemiology, School of Veterinary Medicine , University of California , Tupper Hall 2108, 1 Shields Avenue, Davis , California 95616 , USA.
b Department of Biomedical Sciences , Ross University School of Veterinary Medicine , Post Office Box 334, Basseterre, St. Kitts, West Indies.
J Aquat Anim Health. 2016 Sep;28(3):199-207. doi: 10.1080/08997659.2016.1185051.
In this project we optimized a minimal inhibitory concentration testing protocol for Francisella noatunensis orientalis. Thirty-three F. noatunensis orientalis isolates recovered from different fish species and locations were tested, and Escherichia coli ATCC 25922 was used as a quality control reference strain. A modified cation-adjusted Mueller Hinton broth supplemented with 2% IsoVitalex and 0.1% glucose (MMH) was tested at a pH of 6.4 ± 0.1, 7.1 ± 0.1, and 7.3 ± 0.1. Growth curves generated for F. noatunensis orientalis indicated that MMH at a pH of 6.4 ± 0.1 provided optimal growth. There were no significant differences in the growth curves obtained from isolates recovered from different fish species or from fresh or marine water. The pH of 6.4 ± 0.1 in the MMH media interfered with the inhibitory properties of the potentiated sulfonamides (ormetoprim-sulfadimethoxine and trimethoprim-sulfamethoxazole) when using the E. coli ATCC reference strain. Minimal inhibitory concentrations of eight antimicrobials (gentamicin, enrofloxacin, ampicillin, oxytetracycline, erythromycin, florfenicol, flumequine, and oxolinic acid) were similar for all F. noatunensis orientalis isolates. The in vitro susceptibility data provided here can provide a baseline for monitoring the development of antimicrobial resistance among F. noatunensis orientalis isolates, as well as provide valuable data in the development of potential therapeutics. Received October 27, 2015; accepted April 13, 2016.
在本项目中,我们优化了一种针对东方诺氏弗朗西斯菌的最低抑菌浓度测试方案。对从不同鱼类物种和地点分离出的33株东方诺氏弗朗西斯菌进行了测试,并使用大肠埃希菌ATCC 25922作为质量控制参考菌株。对添加了2%异维生素和0.1%葡萄糖的改良阳离子调节穆勒-欣顿肉汤(MMH)在pH值为6.4±0.1、7.1±0.1和7.3±0.1的条件下进行了测试。东方诺氏弗朗西斯菌的生长曲线表明,pH值为6.4±0.1的MMH能提供最佳生长环境。从不同鱼类物种或淡水或海水中分离出的菌株所获得的生长曲线没有显著差异。当使用大肠埃希菌ATCC参考菌株时,MMH培养基中pH值为6.4±0.1会干扰增效磺胺类药物(奥美普明-磺胺二甲氧嘧啶和甲氧苄啶-磺胺甲恶唑)的抑菌特性。所有东方诺氏弗朗西斯菌分离株对八种抗菌药物(庆大霉素、恩诺沙星、氨苄西林、土霉素、红霉素、氟苯尼考、氟甲喹和恶喹酸)的最低抑菌浓度相似。此处提供的体外药敏数据可为监测东方诺氏弗朗西斯菌分离株中抗菌药物耐药性的发展提供基线,同时也可为潜在治疗方法的开发提供有价值的数据。2015年10月27日收到;2016年4月13日接受。